Narshi Pharmaceutical And Surgical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 27-06-2024
- Paid Up Capital ₹ 0.95 M
as on 27-06-2024
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
as on 27-06-2024
- Satisfied Charges ₹ 0.40 M
as on 27-06-2024
- Revenue 70.07%
(FY 2020)
- Profit 27.69%
(FY 2020)
- Ebitda 27.46%
(FY 2020)
- Net Worth 70.17%
(FY 2020)
- Total Assets 1.69%
(FY 2020)
About Narshi Pharmaceutical And Surgical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.95 M.
The company currently has active open charges totaling ₹4.00 M. The company has closed loans amounting to ₹0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Varsha and Deepak Chhabra serve as directors at the Company.
- CIN/LLPIN
U24239DL2004PTC126195
- Company No.
126195
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 May 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Central Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Narshi Pharmaceutical And Surgical?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Chhabra  | Director | 16-Dec-2006 | Current |
| Varsha | Director | 05-May-2004 | Current |
Financial Performance of Narshi Pharmaceutical And Surgical.
Narshi Pharmaceutical And Surgical Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 70.07% increase. The company also saw a substantial improvement in profitability, with a 27.69% increase in profit. The company's net worth Soared by an impressive increase of 70.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Narshi Pharmaceutical And Surgical?
In 2020, Narshi Pharmaceutical And Surgical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 14 Nov 2006 | ₹4.00 M | Open |
The Nainital Bank Ltd. Creation Date: 26 Apr 2005 | ₹0.40 M | Satisfied |
How Many Employees Work at Narshi Pharmaceutical And Surgical?
Narshi Pharmaceutical And Surgical has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Narshi Pharmaceutical And Surgical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Narshi Pharmaceutical And Surgical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
